Figure 1.
Chemical structures of lipid A derivatives.
A) Lipid A from E. coli. B) Lipid A synthesis intermediate lipid IVa. C) Lipid A from Rhodobacter sphaeroides.
Figure 2.
RSLPS is a partial agonist at horse TLR4/MD-2 and competitive antagonist at human TLR4/MD-2.
HEK293 cells were transiently transfected with horse or human TLR4, MD-2 and CD14, together with reporter constructs NF-κB-luc and phRG-TK. Cells were stimulated 48 hours later for 6 hours. Data are from a representative experiment (n = 3 experiments) and expressed as triplicate mean ±SEM for that experiment, relative to the maximum ECLPS response. A and B) Horse TLR4/MD-2/CD14-transfected cells were stimulated with increasing concentrations of RSLPS or increasing concentrations of ECLPS (A), or increasing concentrations of RSLPS+10 ng/ml ECLPS (B). C) Human TLR4/MD-2/CD14-transfected cells were stimulated with increasing concentrations of ECLPS in the presence of 0, 1, 10 and 100 ng/ml RSLPS.
Figure 3.
RSLPS requires specific residues within horse MD-2 and TLR4, yet is independent of CD14.
HEK293 cells were transiently transfected with combinations of human and horse TLR4 and MD-2, with or without horse CD14, and reporter constructs NF-κB-luc and phRG-TK. Cells were stimulated 48 hours later for 6 hours with 100 ng/ml RSLPS, 10 ng/ml ECLPS, 100 ng/ml RSLPS+10 ng/ml ECLPS, or medium alone. Data are from a representative experiment (n = 3 experiments) and expressed as triplicate mean ±SEM for that experiment, relative to the maximum ECLPS response. A) Cells were transfected with different combinations of human and horse TLR4 and MD-2. B) Horse TLR4/MD-2 was transfected with and without CD14. C) MD-2 mutants were transfected with horse TLR4/CD14. D) TLR4 mutants were transfected with horse MD-2/CD14.
Figure 4.
RSLA and lipid IVa sit differently within the MD-2 pocket.
A) Docking models of RSLA and lipid IVa bound to horse TLR4/MD-2 were overlaid to assess ligand and receptor positioning. The acyl chains of RSLA (blue) sit more deeply in the MD-2 (pink) pocket than lipid IVa (green), and the R2 chain of RSLA protrudes from the MD-2 pocket to contact TLR4* (grey). The 1-PO4 is also moved away from TLR4 due to lowering of the diglucosamine backbone. B) Overlay of RSLA (blue; horse model), lipid IVa (green; horse model) and lipid A (red; human crystal) in situ in the MD-2 pocket. TLR4 and MD-2 have been removed for clarity. The PO4 groups and acyl chains of all three ligands sit somewhat differently to one another within the pocket. Lipid A and RSLA appear to occupy a similar volume within the pocket.
Figure 5.
RSLPS activity requires the presence of both R385 and P442 in horse TLR4.
HEK293 cells were transiently transfected with combinations of human and horse TLR4 and MD-2, together with horse CD14 and reporter constructs NF-κB-luc and phRG-TK. Cells were stimulated 48 hours later for 6 hours. Data are from a representative experiment (n = 3 experiments) and expressed as triplicate mean ±SEM for that experiment, relative to the maximum ECLPS response. A) TLR4 point mutants were transfected with horse MD-2/CD14 and stimulated with 100 ng/ml RSLPS, 10 ng/ml ECLPS, 100 ng/ml RSLPS+10 ng/ml ECLPS or medium alone. B) TLR4 point mutants were transfected with horse MD-2/CD14 and stimulated with 1 µg/ml lipid IVa, 1 µg/ml lipid IVa+10 ng/ml ECLPS, or medium alone.